UY29346A1 - 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2-fenil-indoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
UY29346A1
UY29346A1 UY29346A UY29346A UY29346A1 UY 29346 A1 UY29346 A1 UY 29346A1 UY 29346 A UY29346 A UY 29346A UY 29346 A UY29346 A UY 29346A UY 29346 A1 UY29346 A1 UY 29346A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutically acceptable
prostaglandina
indoles
antagonists
receptor
Prior art date
Application number
UY29346A
Other languages
English (en)
Spanish (es)
Inventor
Keith John Harris
Hans-Jochen Lang
Rose Mappilakunnel Mathew
Stephen James Shimshock
Thaddeus R Nieduzak
Sharon Jackson
Zhaoxia Yang
Kenneth Bordeau
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY29346A1 publication Critical patent/UY29346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY29346A 2005-01-26 2006-01-26 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 UY29346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64730705P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
UY29346A1 true UY29346A1 (es) 2006-08-31

Family

ID=36282872

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29346A UY29346A1 (es) 2005-01-26 2006-01-26 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20070265278A1 (cg-RX-API-DMAC7.html)
EP (1) EP1844011A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008528606A (cg-RX-API-DMAC7.html)
KR (1) KR20070110277A (cg-RX-API-DMAC7.html)
CN (1) CN101146770A (cg-RX-API-DMAC7.html)
AR (1) AR054726A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006209213A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607079A2 (cg-RX-API-DMAC7.html)
CA (1) CA2595728A1 (cg-RX-API-DMAC7.html)
CR (1) CR9214A (cg-RX-API-DMAC7.html)
DO (1) DOP2006000016A (cg-RX-API-DMAC7.html)
GT (1) GT200600030A (cg-RX-API-DMAC7.html)
IL (1) IL184816A0 (cg-RX-API-DMAC7.html)
MA (1) MA29259B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007008277A (cg-RX-API-DMAC7.html)
NO (1) NO20074336L (cg-RX-API-DMAC7.html)
PA (1) PA8661201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060878A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007132166A (cg-RX-API-DMAC7.html)
SG (1) SG158918A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07251A1 (cg-RX-API-DMAC7.html)
TW (1) TW200639151A (cg-RX-API-DMAC7.html)
UY (1) UY29346A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006081343A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705449B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090039735A (ko) * 2006-07-25 2009-04-22 사노피-아벤티스 프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌
EP2316824A1 (en) 2006-08-07 2011-05-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
US8362056B2 (en) * 2007-11-05 2013-01-29 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
EP2626349A4 (en) * 2010-10-06 2014-03-12 Kureha Corp AMINE CONNECTION AND ITS USE
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2762141A4 (en) * 2011-09-29 2015-03-25 Shionogi & Co THERAPEUTIC PHARMACEUTICAL PRODUCT AGAINST ALLERGIC RHINITIS COMPRISING A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6168520B2 (ja) * 2013-09-17 2017-07-26 国立大学法人 千葉大学 インドール化合物、dpプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びdpプロスタノイド受容体アンタゴニストの使用。
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
PH12016501764B1 (en) 2014-03-17 2024-05-17 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN113173877B (zh) * 2020-10-30 2023-10-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法
CN115925606B (zh) * 2023-01-05 2023-10-13 宁夏医科大学 一种5-(3-(磺酰胺基)苯基)-1h-吡咯-2-羧酸衍生物及其制备方法和应用
US12220411B1 (en) 2023-07-25 2025-02-11 The Eye Hospital Of Wenzhou Medical University Application of PTGDS inhibitor in preparation of drug for treating cataracts
CN117599052B (zh) * 2023-07-25 2026-07-24 温州医科大学附属眼视光医院 Ptgds的抑制剂在制备治疗白内障药物上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
JP2004024655A (ja) * 2002-06-27 2004-01-29 Aruze Corp 遊技機
WO2004078719A1 (ja) * 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Also Published As

Publication number Publication date
CN101146770A (zh) 2008-03-19
TW200639151A (en) 2006-11-16
CR9214A (es) 2007-11-23
IL184816A0 (en) 2007-12-03
EP1844011A1 (en) 2007-10-17
JP2008528606A (ja) 2008-07-31
KR20070110277A (ko) 2007-11-16
TNSN07251A1 (en) 2008-12-31
PE20060878A1 (es) 2006-10-18
MA29259B1 (fr) 2008-02-01
NO20074336L (no) 2007-10-23
MX2007008277A (es) 2007-09-07
PA8661201A1 (es) 2006-09-08
SG158918A1 (en) 2010-02-26
AR054726A1 (es) 2007-07-11
CA2595728A1 (en) 2006-08-03
GT200600030A (es) 2006-09-27
US20070265278A1 (en) 2007-11-15
BRPI0607079A2 (pt) 2009-08-04
WO2006081343A1 (en) 2006-08-03
ZA200705449B (en) 2009-01-28
DOP2006000016A (es) 2006-07-31
AU2006209213A1 (en) 2006-08-03
RU2007132166A (ru) 2009-03-10

Similar Documents

Publication Publication Date Title
UY30283A1 (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
JOP20210005B1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
PE20080827A1 (es) N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2
CO6180503A2 (es) Composiciones de inhibidores de chk1
CO6280476A2 (es) Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina
AR092284A1 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDROGENOS (SARMs) Y USOS DE LOS MISMOS
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6290763A2 (es) Derivados de benzamidas, carboxamidas y nicotinamidas como moduladores alostericos positivos y sus composiciones
UY32180A (es) Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
DOP2011000283A (es) Derivados ciclopropil amina
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)